Education
About Us
Working with TipRanks
Follow Us
Austar Lifesciences Ltd. (HK:6118)
:6118
RESEARCH TOOLSreports
Total Valuation
Austar Lifesciences Ltd. has a market cap or net worth of HK$343.43M. The enterprise value is ―.
Market CapHK$343.43M
Enterprise Value―
Share Statistics
Austar Lifesciences Ltd. has 512,582,030 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding512,582,030
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Austar Lifesciences Ltd.’s return on equity (ROE) is 0.02 and return on invested capital (ROIC) is 1.82%.
Return on Equity (ROE)0.02
Return on Assets (ROA)<0.01
Return on Invested Capital (ROIC)1.82%
Return on Capital Employed (ROCE)0.04
Revenue Per Employee1.04M
Profits Per Employee11.13K
Employee Count1,445
Asset Turnover0.72
Inventory Turnover5.03
Valuation Ratios
The current PE Ratio of Austar Lifesciences Ltd. is 17.07. Austar Lifesciences Ltd.’s PEG ratio is 0.16.
PE Ratio17.07
PS Ratio0.00
PB Ratio0.48
Price to Fair Value0.35
Price to FCF3.81
Price to Operating Cash Flow3.81
PEG Ratio0.16
Income Statement
In the last 12 months, Austar Lifesciences Ltd. had revenue of 1.50B and earned 16.08M in profits. Earnings per share was 0.03.
Revenue1.50B
Gross Profit301.22M
Operating Income35.18M
Pretax Income21.17M
Net Income16.08M
EBITDA70.71M
Earnings Per Share (EPS)0.03
Cash Flow
In the last 12 months, operating cash flow was 98.81M and capital expenditures 0.00, giving a free cash flow of 98.81M billion.
Operating Cash Flow98.81M
Free Cash Flow98.81M
Free Cash Flow per Share0.19
Dividends & Yields
Austar Lifesciences Ltd. pays an annual dividend of HK$0.05, resulting in a dividend yield of ―
Dividend Per ShareHK$0.05
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.29
52-Week Price Change-14.10%
50-Day Moving Average0.77
200-Day Moving Average0.69
Relative Strength Index (RSI)35.69
Average Volume (3m)81.33K
Important Dates
Austar Lifesciences Ltd. upcoming earnings date is Sep 2, 2025, TBA Not Confirmed.
Last Earnings DateMar 26, 2025
Next Earnings DateSep 2, 2025
Ex-Dividend DateMay 19, 2015
Financial Position
Austar Lifesciences Ltd. as a current ratio of 1.31, with Debt / Equity ratio of 50.79%
Current Ratio1.31
Quick Ratio1.10
Debt to Market Cap1.29
Net Debt to EBITDA3.33
Interest Coverage Ratio2.05
Taxes
In the past 12 months, Austar Lifesciences Ltd. has paid 7.60M in taxes.
Income Tax7.60M
Effective Tax Rate0.36
Enterprise Valuation
Austar Lifesciences Ltd. EV to EBITDA ratio is 7.21, with an EV/FCF ratio of 6.73.
EV to Sales0.34
EV to EBITDA7.21
EV to Free Cash Flow6.73
EV to Operating Cash Flow5.16
Balance Sheet
Austar Lifesciences Ltd. has HK$167.81M in cash and marketable securities with ¥401.95M in debt, giving a net cash position of HK$234.15M billion.
Cash & Marketable SecuritiesHK$167.81M
Total Debt¥401.95M
Net CashHK$234.15M
Net Cash Per ShareHK$0.46
Tangible Book Value Per ShareHK$1.47
Margins
Gross margin is 20.08%, with operating margin of 2.34%, and net profit margin of 1.07%.
Gross Margin20.08%
Operating Margin2.34%
Pretax Margin1.41%
Net Profit Margin1.07%
EBITDA Margin4.71%
EBIT Margin2.32%
Analyst Forecast
The average price target for Austar Lifesciences Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-16.75%
EPS Growth Forecast―